ClinicalTrials.gg
CompletedNCT05393271Updated Apr 1, 2025Results posted

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

A Phase 1 interventional study of VH4011499 and Placebo in HIV Infections, sponsored by ViiV Healthcare. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
110th of 210
73 · median 82
Started
2022
with 5 others
Phase 1
83 of 266
9 open now
Registered
228th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 110th largest by enrollment of the 210 interventional ones that give a count, is one of 6 that started in 2022, is one of 83 in phase 1, and was the 228th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults. The study will be conducted in 3 parts: Part 1 will investigate single ascending doses (SAD) and Part 2 will investigate multiple ascending doses (MAD). Part 3 will investigate single dose of a new formulation of VH4011499. The transition from SAD to MAD will be based on the assessment of the Safety and Dose Escalation Committee.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • GSK4011499
  • VH4011499
  • First-time-in-human
  • HIV-1 capsid inhibitor
  • Single ascending doses
  • Multiple ascending doses
  • Drug-drug Interaction
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy.
  • Participants must have two consecutive Severe Acute Respiratory Syndrome Coronavirus 2 (SARs-CoV-2) Polymerase chain reaction (PCR) negative results prior to dosing.
  • Participants must have body weight > 50 kilograms (kg) and (BMI) within the range 19-32 kilograms per meter square (kg/m\^2).
  • Male or female participants (either of non- or of child-bearing potential and using acceptable ).
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neurological or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug or interfering with the interpretation of data.
  • Abnormal blood pressure.
  • Lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Breast cancer within the past 10 years.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • corrected for heart rate according to Fridericia's formula (QTcF) greater than (>)450 milliseconds (msec).
  • Past or intended use of over-the-counter or prescription medication including herbal medications within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study, unless in the opinion of the Investigator and Sponsor, the medication will not interfere with the study medications, procedures, or compromise participant safety.
  • (s) within 1 month prior to screening or plans to receive such vaccines during the study.
  • Exposure to more than 4 products within 12 months prior to dosing.
  • Current enrollment or recent past participation in another investigational study.
  • >1.5 times (ULN), total >1.5 times ULN, and/or estimated serum less than 60 milliliters per minute.
  • History of or current infection with or .
  • Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) test, having signs and symptoms, or having contact with known Coronavirus Disease-2019 (COVID-19) positive person/s within 14 days.
  • Positive antibody test.
  • Use of tobacco or nicotine-containing products, regular alcohol consumption and/or regular use of known drugs of abuse.
  • Sensitivity to the study drug, or components thereof midazolam, contained therein, benzodiazepines, or drug or other allergy that, contraindicates participation in the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
73 participants (actual)

Study arms

  • Placebo comparator
    Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)

    Healthy participants were given a single dose of placebo on Day 1 and were followed up until Day 28.

    Drug: Placebo

  • Placebo comparator
    Part 1 (SAD): VH4011499 25 mg PiB

    Healthy participants were given a single dose of 25 mg VH4011499 on Day 1 and were followed up until Day 28.

    Drug: VH4011499

  • Experimental
    Part 1 (SAD): VH4011499 125 mg PiB

    Healthy participants were given a single dose of 125 mg VH4011499 on Day 1 and were followed up until Day 28.

    Drug: VH4011499

  • Experimental
    Part 1 (SAD): VH4011499 200 mg PiB

    Healthy participants were given a single dose of 200 mg VH4011499 on Day 1 and were followed up until Day 28.

    Drug: VH4011499

  • Experimental
    Part 1 (SAD): VH4011499 625 mg PiB

    Healthy participants were given a single dose of 625 mg VH4011499 on Day 1 and were followed up until Day 28.

    Drug: VH4011499

  • Experimental
    Part 1 (SAD): VH4011499 1875 mg PiB

    Healthy participants were given a single dose of 1875 mg VH4011499 on Day 1 and were followed up until Day 28.

    Drug: VH4011499

  • Placebo comparator
    Part 2 Multiple Ascending Dose (MAD): Placebo PiB

    Healthy participants were given a dose of placebo once daily for a 14-day period and were followed up until Day 42.

    Drug: Placebo

  • Experimental
    Part 2 (MAD): VH4011499 200 mg PiB

    Healthy participants were given a dose of VH4011499 200 mg PiB once daily for a 14-day period and were followed up until Day 42.

    Drug: VH4011499

  • Experimental
    Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB

    Healthy participants were given a dose of VH4011499 300 mg once daily and a single dose of Midazolam on Days 1, 2, and 15, and were followed up until Day 42.

    Drug: VH4011499 · Drug: Midazolam

  • Experimental
    Part 2 (MAD): VH4011499 400 mg PiB

    Healthy participants were given a dose of VH4011499 400 mg PiB once daily for a 14-day period and were followed up until Day 42.

    Drug: VH4011499

  • Experimental
    Part 3 (Single dose): VH4011499 200 mg tablet

    Healthy participants were given a dose of VH4011499 200 mg tablet on Day 1 and were followed up until Day 28.

    Drug: VH4011499

Interventions

  • VH4011499 will be administered.

    Also known as: GSK4011499

  • DrugPlacebo

    Placebo will be administered.

  • Midazolam will be administered

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.

    Time frame: Up to Day 28

  2. Part 2: Number of Participants With AEs

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.

    Time frame: Up to Day 42

  3. Part 3: Number of Participants With AEs

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.

    Time frame: Up to Day 28

  4. Part 1: Number of Participants With AEs by Severity

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.

    Time frame: Up to Day 28

  5. Part 2: Number of Participants With AEs by Severity

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.

    Time frame: Up to Day 42

  6. Part 3: Number of Participants With AEs by Severity

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.

    Time frame: Up to Day 28

  7. Part 2: Number of Participants Discontinuing Treatment Due to AEs

    Number of participants who discontinued treatment due to AEs are presented.

    Time frame: Up to Day 42

  8. Part 1: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.

    Time frame: Up to Day 28

  9. Part 1: Absolute Values of Liver Panel Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST.

    Time frame: Up to Day 28

  10. Part 2: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.

    Time frame: Up to Day 42

  11. Part 2: Absolute Values of Liver Panel Parameters: ALT, ALP and AST

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST

    Time frame: Up to Day 42

  12. Part 3: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.

    Time frame: Up to Day 28

  13. Part 3: Absolute Values of Liver Panel Parameters: ALT, ALP and AST

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST

    Time frame: Up to Day 28

  14. Part 1: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

    Time frame: From Baseline (Day 1) and up to Day 28

  15. Part 1: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

    Time frame: From Baseline (Day 1) and up to Day 28

  16. Part 2: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. Standard Deviation (SD)=0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.

    Time frame: From Baseline (Day 1) and up to Day 42

  17. Part 2: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. SD=0.00 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.00.

    Time frame: From Baseline (Day 1) and up to Day 42

  18. Part 3: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

    Time frame: From Baseline (Day 1) and up to Day 28

  19. Part 3: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

    Time frame: From Baseline (Day 1) and up to Day 28

  20. Part 1: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.

    Time frame: Up to Day 28

  21. Part 2: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.

    Time frame: Up to Day 42

  22. Part 3: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.

    Time frame: Up to Day 28

  23. Part 1: Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinity (0-inf) Following Single Dose Administration of VH4011499

    Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis to determine AUC(0-inf). For AUC, a linear trapezoidal method was employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method was used for those arising from decreasing concentrations. Geometric Coefficient of Variation was expressed in percentages.

    Time frame: At Day 1

  24. Part 2: AUC Over a Dosing Interval From Time of Dosing to the Time of the Subsequent Dose (0-t) Following Repeat Dose Administration of VH4011499

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine AUC(0-t). For AUC, a linear trapezoidal method was employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method was used for those arising from decreasing concentrations.

    Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group

  25. Part 1: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of VH4011499.

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Cmax.

    Time frame: At Day 1

  26. Part 1: Time to Maximum Observed Plasma Concentration (Tmax) Following Single Dose Administration of VH4011499

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Tmax.

    Time frame: At Day 1

  27. Part 1: Apparent Terminal Half-life (T1/2) Following Single Dose Administration of VH4011499

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine T1/2.

    Time frame: At Day 1

  28. Part 2: Cmax Following Repeat Dose Administration of VH4011499

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Cmax.

    Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group

  29. Part 2: Tmax Following Repeat Dose Administration of VH4011499

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Tmax.

    Time frame: At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group

  30. Part 2: T1/2 Following Repeat Dose Administration of VH4011499

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine T1/2.

    Time frame: At Day 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Day 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group

07

Results

Posted Apr 1, 2025

Participant flow

Participant flow — Overall Study
MilestonePart 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiBPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiBPart 3 (Single Dose): VH4011499 200 mg Tablet
Started106666676866
Completed106666666866
Not completed00000010000
Withdrew: Physician decision00000010000

Outcome measures

PrimaryPart 1: Number of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Adverse Events (AEs)
ParticipantsPart 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
Part 1: Number of Participants With Adverse Events (AEs)321311
PrimaryPart 2: Number of Participants With AEs

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.

Time frame:
Up to Day 42
Reported as:
Count of participants · Participants
Part 2: Number of Participants With AEs
ParticipantsPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
Part 2: Number of Participants With AEs2332
PrimaryPart 3: Number of Participants With AEs

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Part 3: Number of Participants With AEs
ParticipantsPart 3 (Single Dose): VH4011499 200 mg Tablet
Part 3: Number of Participants With AEs1
PrimaryPart 1: Number of Participants With AEs by Severity

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Part 1: Number of Participants With AEs by Severity
ParticipantsPart 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
Grade 1111211
Grade 2100000
Grade 3100100
Grade 4010000
Grade 5000000
PrimaryPart 2: Number of Participants With AEs by Severity

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.

Time frame:
Up to Day 42
Reported as:
Count of participants · Participants
Part 2: Number of Participants With AEs by Severity
ParticipantsPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
Grade 12332
Grade 20000
Grade 30000
Grade 40000
Grade 50000
PrimaryPart 3: Number of Participants With AEs by Severity

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a study intervention whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild symptoms causing no or minimal interference with usual social \& functional activities with intervention not indicated, 2=Moderate symptoms causing greater than minimal interference with usual social \& functional activities with intervention indicated, 3=Severe symptoms causing inability to perform usual social \& functional activities with intervention or hospitalization indicated, 4=Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability or death, 5=Death.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Part 3: Number of Participants With AEs by Severity
ParticipantsPart 3 (Single Dose): VH4011499 200 mg Tablet
Grade 11
Grade 20
Grade 30
Grade 40
Grade 50
PrimaryPart 2: Number of Participants Discontinuing Treatment Due to AEs

Number of participants who discontinued treatment due to AEs are presented.

Time frame:
Up to Day 42
Reported as:
Count of participants · Participants
Part 2: Number of Participants Discontinuing Treatment Due to AEs
ParticipantsPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
Part 2: Number of Participants Discontinuing Treatment Due to AEs0000
PrimaryPart 1: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.

Time frame:
Up to Day 28
Reported as:
Mean · Micromoles per Liter (μmol/L)
Part 1: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
Micromoles per Liter (μmol/L)Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
Direct Bilirubin, Baseline (Day 1)2.0520 ± 0.721002.8500 ± 1.396212.2800 ± 0.883041.9950 ± 0.698102.5650 ± 0.936613.1350 ± 1.28724
Direct Bilirubin, Day 21.9152 ± 0.889642.7075 ± 0.523351.9950 ± 0.598911.9665 ± 0.492652.4510 ± 0.579053.2205 ± 1.41183
Direct Bilirubin, Day 31.9665 ± 0.994652.5650 ± 0.648901.8525 ± 0.451341.7385 ± 0.566282.3940 ± 0.666683.1350 ± 1.34501
Direct Bilirubin, Day 41.6416 ± 0.868952.7075 ± 0.783001.9095 ± 0.488671.6245 ± 0.814722.1375 ± 0.655622.7075 ± 1.01693
Direct Bilirubin, Day 52.0007 ± 0.756412.7930 ± 0.842372.3085 ± 0.515841.7670 ± 0.353222.3940 ± 0.709193.2205 ± 1.33519
Direct Bilirubin, Day 61.8639 ± 0.762392.8785 ± 0.957702.5365 ± 0.696011.9380 ± 0.514902.2515 ± 0.634473.0210 ± 1.28724
Direct Bilirubin, Day 72.1375 ± 0.842562.9640 ± 0.769822.8044 ± 0.393671.6815 ± 0.678992.5650 ± 0.741443.3630 ± 1.19292
Direct Bilirubin, Day 141.8620 ± 0.998722.3256 ± 1.030271.9095 ± 0.643621.4022 ± 0.442621.9494 ± 0.259332.0805 ± 0.93296
Direct Bilirubin, Day 211.7955 ± 0.951232.3256 ± 0.751232.1660 ± 0.503411.4820 ± 0.279241.7385 ± 0.273962.2230 ± 1.08150
Direct Bilirubin, Day 281.7613 ± 0.756412.1945 ± 0.464121.8810 ± 0.432601.7670 ± 0.454571.8525 ± 0.775492.6220 ± 1.56226
Total Bilirubin, Baseline (Day 1)9.4050 ± 3.1479312.8250 ± 5.5935610.5450 ± 4.7655511.6850 ± 2.2728611.9700 ± 2.6491213.6800 ± 6.11788
Total Bilirubin, Day 210.7901 ± 3.1607511.9415 ± 2.8906914.0790 ± 5.3122010.8015 ± 2.3029013.5945 ± 3.9199718.5250 ± 9.28747
Total Bilirubin, Day 310.4310 ± 2.8974811.9985 ± 3.0232015.1620 ± 7.8419211.3145 ± 2.7898012.5115 ± 3.7610917.1000 ± 7.15263
Total Bilirubin, Day 49.6444 ± 3.8238511.2290 ± 2.6239812.6825 ± 6.8463410.1460 ± 4.3686010.9155 ± 3.6297415.6465 ± 7.08175
Total Bilirubin, Day 511.0637 ± 3.5045012.4260 ± 2.9193814.6490 ± 4.954489.9180 ± 2.3069212.4545 ± 3.7533117.7270 ± 7.77602
Total Bilirubin, Day 610.1574 ± 3.0950512.3690 ± 2.2049514.5350 ± 4.4420510.9725 ± 2.7918912.1980 ± 4.5701116.0455 ± 6.69431
Total Bilirubin, Day 711.3373 ± 3.3490113.1670 ± 3.6739116.1766 ± 4.752149.5475 ± 4.1752312.4545 ± 4.0515318.1260 ± 6.43469
Total Bilirubin, Day 149.1390 ± 4.160719.4050 ± 4.371389.9750 ± 3.820117.5582 ± 2.482158.2422 ± 1.2876210.2885 ± 4.38563
Total Bilirubin, Day 219.3195 ± 4.079589.7128 ± 2.8979311.0580 ± 2.836068.2365 ± 2.106618.0370 ± 1.6789410.5735 ± 4.85401
Total Bilirubin, Day 289.5247 ± 3.7473310.4595 ± 2.493129.0345 ± 1.561329.7185 ± 2.678589.1770 ± 2.7861313.4805 ± 9.10929
PrimaryPart 1: Absolute Values of Liver Panel Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST.

Time frame:
Up to Day 28
Reported as:
Mean · International Units per Liter (IU/L)
Part 1: Absolute Values of Liver Panel Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)
International Units per Liter (IU/L)Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
ALP, Baseline (Day 1)56.4 ± 20.8257.2 ± 18.9653.7 ± 6.5063.0 ± 5.1472.0 ± 29.3955.0 ± 8.07
ALP, Day 252.3 ± 17.2356.3 ± 20.5451.2 ± 5.3459.3 ± 5.9967.8 ± 22.6348.8 ± 7.05
ALP, Day 353.1 ± 16.1154.8 ± 19.3650.7 ± 6.8658.2 ± 6.9166.3 ± 21.0851.7 ± 8.12
ALP, Day 454.5 ± 15.6355.5 ± 19.2752.5 ± 6.5365.0 ± 9.8269.5 ± 24.6052.7 ± 8.21
ALP, Day 553.9 ± 14.8954.0 ± 17.5552.2 ± 7.2262.2 ± 9.4168.0 ± 21.5653.0 ± 9.34
ALP, Day 654.2 ± 15.8553.3 ± 17.4552.3 ± 8.3665.0 ± 9.9067.5 ± 18.7252.7 ± 9.14
ALP, Day 754.6 ± 15.8854.2 ± 17.5249.4 ± 4.5665.0 ± 10.6466.7 ± 22.7154.0 ± 10.00
ALP, Day 1452.8 ± 16.5959.6 ± 24.9953.2 ± 7.1463.6 ± 9.7177.2 ± 22.6253.2 ± 7.83
ALP, Day 2158.5 ± 22.1558.8 ± 21.4852.8 ± 6.2466.8 ± 11.7270.2 ± 20.4951.3 ± 6.71
ALP, Day 2856.1 ± 17.6259.0 ± 19.3855.7 ± 7.6168.5 ± 12.1468.7 ± 20.7551.5 ± 7.77
ALT, Baseline (Day 1)13.9 ± 4.3828.5 ± 16.0124.7 ± 9.0316.0 ± 4.3423.8 ± 13.1121.7 ± 3.44
ALT, Day 214.2 ± 4.9634.0 ± 24.6623.2 ± 8.9816.0 ± 4.9819.5 ± 10.5621.8 ± 8.93
ALT, Day 315.7 ± 5.5633.7 ± 25.9522.3 ± 8.0416.5 ± 5.9217.5 ± 8.8020.5 ± 8.48
ALT, Day 416.0 ± 6.3630.0 ± 19.9323.2 ± 7.3115.8 ± 5.7818.0 ± 8.7220.3 ± 7.28
ALT, Day 516.1 ± 5.3627.2 ± 16.8222.2 ± 6.7916.2 ± 6.1118.2 ± 9.3319.2 ± 4.96
ALT, Day 617.4 ± 6.4524.7 ± 14.3522.0 ± 5.4417.2 ± 6.4917.8 ± 8.3319.2 ± 4.49
ALT, Day 718.7 ± 7.5623.5 ± 12.6323.6 ± 5.4617.3 ± 6.5318.2 ± 9.1520.0 ± 5.59
ALT, Day 1419.7 ± 6.4021.2 ± 9.5021.5 ± 6.0916.4 ± 3.4421.6 ± 9.2419.7 ± 3.72
ALT, Day 2120.5 ± 11.4026.0 ± 20.2524.8 ± 10.5518.2 ± 3.9219.5 ± 9.7118.7 ± 3.61
ALT, Day 2824.9 ± 17.3928.2 ± 24.8123.8 ± 6.6216.8 ± 5.4218.5 ± 7.4818.2 ± 3.54
AST, Baseline (Day 1)15.0 ± 3.5320.7 ± 9.6520.3 ± 3.2716.2 ± 2.6420.0 ± 8.0721.7 ± 4.27
AST, Day 214.2 ± 3.4323.0 ± 13.5519.2 ± 3.6614.3 ± 3.0115.0 ± 3.2918.3 ± 5.57
AST, Day 315.3 ± 3.1621.0 ± 9.8618.2 ± 3.4914.0 ± 2.3714.7 ± 2.1617.8 ± 4.45
AST, Day 415.1 ± 3.3117.5 ± 6.8319.3 ± 3.6114.0 ± 2.2814.8 ± 2.6417.8 ± 3.54
AST, Day 515.2 ± 2.5315.5 ± 4.5118.5 ± 3.0214.2 ± 2.0414.8 ± 2.4017.0 ± 2.76
AST, Day 615.1 ± 3.4114.8 ± 3.9718.3 ± 3.5614.3 ± 2.0715.0 ± 1.7917.2 ± 3.31
AST, Day 716.0 ± 3.6217.0 ± 5.1419.0 ± 2.5514.7 ± 2.4214.8 ± 2.4819.2 ± 5.19
AST, Day 1418.0 ± 5.6117.4 ± 6.6620.7 ± 5.6517.4 ± 2.3017.6 ± 3.2119.5 ± 4.76
AST, Day 2118.6 ± 10.0718.4 ± 6.1520.8 ± 2.5617.5 ± 2.0715.8 ± 3.0619.0 ± 3.46
AST, Day 2820.3 ± 10.1932.0 ± 26.5022.8 ± 5.8515.7 ± 2.4215.8 ± 2.7119.8 ± 4.49
PrimaryPart 2: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.

Time frame:
Up to Day 42
Reported as:
Mean · μmol/L
Part 2: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
μmol/LPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
Direct Bilirubin, Baseline (Day 1)1.6856 ± 0.348051.7670 ± 0.883041.6031 ± 0.747822.5365 ± 1.12089
Direct Bilirubin, Day 21.8126 ± 0.354591.9665 ± 0.66448—2.8785 ± 1.15177
Direct Bilirubin, Day 31.8810 ± 0.24183—2.1161 ± 0.56298—
Direct Bilirubin, Day 51.9238 ± 0.645512.3370 ± 0.71466—2.4510 ± 0.75447
Direct Bilirubin, Day 61.8810 ± 0.24183—2.4795 ± 0.60630—
Direct Bilirubin, Day 72.1375 ± 0.407062.0805 ± 0.81949—3.2490 ± 1.23310
Direct Bilirubin, Day 81.6245 ± 0.36275—2.2444 ± 0.43296—
Direct Bilirubin, Day 112.1803 ± 0.564992.1660 ± 0.62752—3.1065 ± 1.18678
Direct Bilirubin, Day 121.3680 ± 0.24183—2.2871 ± 0.48312—
Direct Bilirubin, Day 142.1375 ± 0.452422.1660 ± 0.61813—3.0495 ± 1.15683
Direct Bilirubin, Day 151.9665 ± 0.12092—2.2444 ± 0.37058—
Direct Bilirubin, Day 211.9665 ± 0.355961.9950 ± 0.61813—2.8785 ± 1.17190
Direct Bilirubin, Day 221.7955 ± 0.36275—2.0734 ± 0.58838—
Direct Bilirubin, Day 281.5048 ± 0.389941.3965 ± 0.586571.2825 ± 0.447781.8525 ± 0.76026
Direct Bilirubin, Day 351.4250 ± 0.336251.4535 ± 0.492651.3253 ± 0.270372.8500 ± 1.72927
Direct Bilirubin, Day 421.5105 ± 0.365421.1115 ± 0.504381.7100 ± 0.342002.5650 ± 1.97947
Total Bilirubin, Baseline (Day 1)10.5776 ± 2.9854510.0890 ± 5.907809.5760 ± 4.3692312.8250 ± 6.63163
Total Bilirubin, Day 212.1752 ± 1.7580613.6800 ± 6.64924—16.8720 ± 7.08416
Total Bilirubin, Day 312.1410 ± 1.69281—12.5044 ± 4.14193—
Total Bilirubin, Day 512.0128 ± 2.8145813.7370 ± 5.74282—15.7320 ± 4.92171
Total Bilirubin, Day 610.0890 ± 1.93464—12.7181 ± 3.00651—
Total Bilirubin, Day 712.8250 ± 2.4383713.2240 ± 6.58176—16.4445 ± 6.72047
Total Bilirubin, Day 89.9180 ± 1.69281—13.1456 ± 2.44141—
Total Bilirubin, Day 1112.7395 ± 2.4839213.8510 ± 5.61547—16.4445 ± 6.63464
Total Bilirubin, Day 1210.6875 ± 0.36275—13.8724 ± 4.15402—
Total Bilirubin, Day 1411.7563 ± 2.1237813.4235 ± 4.72994—15.6465 ± 6.66132
Total Bilirubin, Day 1511.7990 ± 2.66014—13.9793 ± 3.89270—
Total Bilirubin, Day 2112.5258 ± 0.2151711.9700 ± 4.29070—16.9575 ± 7.40445
Total Bilirubin, Day 2211.2005 ± 2.29739—12.2479 ± 3.78959—
Total Bilirubin, Day 288.5842 ± 2.342768.1225 ± 4.030316.6904 ± 2.719838.3220 ± 3.44499
Total Bilirubin, Day 359.1770 ± 2.045348.2365 ± 2.287617.5454 ± 2.2913615.0195 ± 10.22140
Total Bilirubin, Day 429.7755 ± 3.146437.4385 ± 2.677128.6141 ± 2.3693413.0530 ± 11.74742
PrimaryPart 2: Absolute Values of Liver Panel Parameters: ALT, ALP and AST

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST

Time frame:
Up to Day 42
Reported as:
Mean · IU/L
Part 2: Absolute Values of Liver Panel Parameters: ALT, ALP and AST
IU/LPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
ALP, Baseline (Day 1)56.0 ± 16.7859.5 ± 19.6969.0 ± 22.4353.8 ± 10.55
ALP, Day 253.8 ± 12.1558.3 ± 20.97—53.2 ± 10.91
ALP, Day 347.0 ± 18.38—68.6 ± 22.56—
ALP, Day 552.5 ± 10.3462.2 ± 23.59—54.3 ± 11.04
ALP, Day 647.0 ± 18.38—69.3 ± 21.99—
ALP, Day 750.3 ± 12.0459.3 ± 20.65—54.2 ± 10.46
ALP, Day 847.0 ± 18.38—71.9 ± 24.31—
ALP, Day 1150.3 ± 12.9254.0 ± 18.07—51.2 ± 9.77
ALP, Day 1247.0 ± 18.38—64.0 ± 19.95—
ALP, Day 1451.8 ± 12.7661.0 ± 19.78—49.7 ± 9.20
ALP, Day 1550.5 ± 23.33—66.5 ± 22.60—
ALP, Day 2149.5 ± 12.4051.8 ± 14.30—50.8 ± 10.53
ALP, Day 2247.0 ± 18.38—63.8 ± 18.72—
ALP, Day 2853.4 ± 11.6760.0 ± 14.8562.6 ± 19.2651.3 ± 10.67
ALP, Day 3547.7 ± 12.7163.0 ± 34.8965.5 ± 17.8849.0 ± 11.37
ALP, Day 4252.2 ± 12.6460.3 ± 18.6066.5 ± 22.5353.5 ± 10.65
ALT, Baseline (Day 1)23.6 ± 8.3015.8 ± 4.6219.5 ± 5.7119.8 ± 6.24
ALT, Day 219.8 ± 6.3016.0 ± 4.90—19.0 ± 6.03
ALT, Day 323.5 ± 12.02—16.6 ± 4.47—
ALT, Day 517.0 ± 5.3516.0 ± 4.65—17.3 ± 6.31
ALT, Day 619.5 ± 9.19—15.6 ± 5.48—
ALT, Day 716.0 ± 4.2414.5 ± 3.62—18.8 ± 7.47
ALT, Day 820.5 ± 7.78—18.1 ± 7.86—
ALT, Day 1115.3 ± 3.7712.5 ± 3.73—19.5 ± 8.76
ALT, Day 1218.0 ± 8.49—14.8 ± 5.85—
ALT, Day 1416.8 ± 4.1912.2 ± 3.19—18.7 ± 7.31
ALT, Day 1526.0 ± 16.97—18.1 ± 7.75—
ALT, Day 2116.0 ± 5.3512.3 ± 3.33—18.3 ± 8.19
ALT, Day 2219.5 ± 10.61—17.0 ± 8.72—
ALT, Day 2820.6 ± 9.2916.7 ± 6.0220.9 ± 7.5922.3 ± 11.41
ALT, Day 3522.0 ± 11.7628.0 ± 27.7918.4 ± 5.9318.3 ± 4.13
ALT, Day 4224.2 ± 10.3814.8 ± 3.6620.5 ± 5.9321.8 ± 4.45
AST, Baseline (Day 1)23.3 ± 7.4517.3 ± 3.4418.9 ± 2.7017.7 ± 3.27
AST, Day 219.6 ± 2.6116.5 ± 3.02—15.3 ± 3.08
AST, Day 319.0 ± 8.49—17.0 ± 2.98—
AST, Day 518.0 ± 2.8316.8 ± 2.04—14.0 ± 2.10
AST, Day 616.0 ± 7.07—16.0 ± 3.07—
AST, Day 717.3 ± 1.7116.3 ± 2.25—14.7 ± 1.63
AST, Day 817.0 ± 5.66—18.0 ± 4.69—
AST, Day 1115.5 ± 2.3815.8 ± 3.54—13.3 ± 2.50
AST, Day 1216.5 ± 4.95—15.9 ± 2.70—
AST, Day 1417.3 ± 3.1016.7 ± 3.50—13.8 ± 2.14
AST, Day 1520.0 ± 9.90—17.6 ± 4.17—
AST, Day 2116.5 ± 2.0815.7 ± 2.73—15.0 ± 3.16
AST, Day 2218.0 ± 4.24—16.6 ± 3.16—
AST, Day 2820.2 ± 4.2717.5 ± 3.7322.6 ± 8.1920.7 ± 7.84
AST, Day 3520.0 ± 6.6326.3 ± 19.3420.5 ± 3.5520.2 ± 7.91
AST, Day 4221.7 ± 4.9316.3 ± 1.7519.8 ± 4.2020.7 ± 3.27
PrimaryPart 3: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin.

Time frame:
Up to Day 28
Reported as:
Mean · IU/L
Part 3: Absolute Values of Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
IU/LPart 3 (Single Dose): VH4011499 200 mg Tablet
Direct Bilirubin, Baseline (Day 1)1.4250 ± 0.69810
Direct Bilirubin, Day 22.1375 ± 0.97784
Direct Bilirubin, Day 32.2515 ± 1.05642
Direct Bilirubin, Day 41.9665 ± 0.94747
Direct Bilirubin, Day 51.7784 ± 0.44591
Direct Bilirubin, Day 62.3085 ± 1.11216
Direct Bilirubin, Day 71.9950 ± 0.89619
Direct Bilirubin, Day 141.9665 ± 0.69038
Direct Bilirubin, Day 211.8525 ± 0.69601
Direct Bilirubin, Day 282.6790 ± 2.39074
Total Bilirubin, Baseline (Day 1)7.6950 ± 3.19912
Total Bilirubin, Day 214.2500 ± 7.57873
Total Bilirubin, Day 313.8225 ± 7.43283
Total Bilirubin, Day 412.2550 ± 6.56575
Total Bilirubin, Day 510.8756 ± 2.84755
Total Bilirubin, Day 614.5920 ± 8.80586
Total Bilirubin, Day 711.2290 ± 5.55123
Total Bilirubin, Day 1411.7705 ± 6.12879
Total Bilirubin, Day 218.2365 ± 3.08827
Total Bilirubin, Day 2814.4495 ± 15.05412
PrimaryPart 3: Absolute Values of Liver Panel Parameters: ALT, ALP and AST

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST

Time frame:
Up to Day 28
Reported as:
Mean · μmol/L
Part 3: Absolute Values of Liver Panel Parameters: ALT, ALP and AST
μmol/LPart 3 (Single Dose): VH4011499 200 mg Tablet
ALP, Baseline (Day 1)52.0 ± 8.12
ALP, Day 250.7 ± 7.99
ALP, Day 351.0 ± 8.20
ALP, Day 454.3 ± 7.39
ALP, Day 556.6 ± 7.73
ALP, Day 654.2 ± 6.62
ALP, Day 754.7 ± 6.12
ALP, Day 1454.7 ± 10.39
ALP, Day 2152.7 ± 7.61
ALP, Day 2856.3 ± 8.52
ALT, Baseline (Day 1)12.7 ± 4.03
ALT, Day 215.2 ± 6.74
ALT, Day 315.0 ± 6.60
ALT, Day 415.0 ± 8.32
ALT, Day 513.0 ± 4.42
ALT, Day 615.2 ± 6.85
ALT, Day 715.0 ± 5.87
ALT, Day 1417.5 ± 8.96
ALT, Day 2119.2 ± 10.26
ALT, Day 2815.0 ± 4.38
AST, Baseline16.7 ± 1.63
AST, Day 217.3 ± 3.20
AST, Day 316.3 ± 2.34
AST, Day 416.5 ± 2.26
AST, Day 516.6 ± 1.14
AST, Day 617.2 ± 1.83
AST, Day 716.3 ± 1.63
AST, Day 1419.3 ± 3.44
AST, Day 2121.0 ± 9.03
AST, Day 2818.5 ± 3.27
PrimaryPart 1: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

Time frame:
From Baseline (Day 1) and up to Day 28
Reported as:
Mean · IU/L
Part 1: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
IU/LPart 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
Direct Bilirubin, Baseline (Day 1)2.0520 ± 0.721002.8500 ± 1.396212.2800 ± 0.883041.9950 ± 0.698102.5650 ± 0.936613.1350 ± 1.28724
Direct Bilirubin, Day 2-0.1368 ± 0.54553-0.1425 ± 1.54248-0.2850 ± 0.84237-0.0285 ± 0.45134-0.1140 ± 0.627520.0855 ± 0.79289
Direct Bilirubin, Day 3-0.0855 ± 0.99465-0.2850 ± 1.53963-0.4275 ± 0.90968-0.2565 ± 0.35459-0.1710 ± 0.787340.0000 ± 1.14965
Direct Bilirubin, Day 4-0.4104 ± 0.49822-0.1425 ± 1.53868-0.3705 ± 0.90754-0.3705 ± 0.62518-0.4275 ± 0.55936-0.4275 ± 0.84985
Direct Bilirubin, Day 5-0.0513 ± 0.58157-0.0570 ± 1.843840.0285 ± 1.02267-0.2280 ± 0.73085-0.1710 ± 0.666680.0855 ± 1.00148
Direct Bilirubin, Day 6-0.1881 ± 0.493310.0285 ± 2.018720.2565 ± 1.30117-0.0570 ± 0.56886-0.3135 ± 0.63447-0.1140 ± 1.30976
Direct Bilirubin, Day 70.0855 ± 0.565710.1140 ± 1.779280.4104 ± 1.00148-0.3135 ± 0.476560.0000 ± 0.611790.2280 ± 1.21719
Direct Bilirubin, Day 14-0.2280 ± 0.61655-0.4104 ± 1.21277-0.3705 ± 1.11040-0.6498 ± 0.89999-0.7866 ± 0.98678-1.0545 ± 1.05087
Direct Bilirubin, Day 21-0.2565 ± 0.50502-0.4104 ± 1.12523-0.1140 ± 1.09047-0.5130 ± 0.72549-0.8265 ± 0.88138-0.9120 ± 0.97735
Direct Bilirubin, Day 28-0.2907 ± 0.39532-0.6555 ± 1.80457-0.3990 ± 0.98331-0.2280 ± 0.70643-0.7125 ± 0.77549-0.5130 ± 1.16982
Total Bilirubin, Baseline (Day 1)9.4050 ± 3.1479312.8250 ± 5.5935610.5450 ± 4.7655511.6850 ± 2.2728611.9700 ± 2.6491213.6800 ± 6.11788
Total Bilirubin, Day 21.3851 ± 2.24764-0.8835 ± 4.854013.5340 ± 4.59817-0.8835 ± 2.061711.6245 ± 2.722614.8450 ± 6.74934
Total Bilirubin, Day 31.0260 ± 2.05042-0.8265 ± 5.516094.6170 ± 7.54418-0.3705 ± 1.794820.5415 ± 2.920883.4200 ± 7.47252
Total Bilirubin, Day 40.2394 ± 2.41185-1.5960 ± 5.053812.1375 ± 6.66747-1.5390 ± 3.11577-1.0545 ± 2.335681.9665 ± 5.79158
Total Bilirubin, Day 51.6587 ± 2.37773-0.3990 ± 5.956764.1040 ± 5.26169-1.7670 ± 2.505410.4845 ± 1.977744.0470 ± 7.46913
Total Bilirubin, Day 60.7524 ± 2.27886-0.4560 ± 6.194513.9900 ± 6.70064-0.7125 ± 1.830310.2280 ± 3.360782.3655 ± 8.26581
Total Bilirubin, Day 71.9323 ± 2.556820.3420 ± 6.369845.2326 ± 5.27972-2.1375 ± 2.498590.4845 ± 2.426554.4460 ± 6.95867
Total Bilirubin, Day 14-0.3610 ± 1.91460-2.9070 ± 6.29108-0.5700 ± 4.06486-4.0698 ± 3.91698-3.7278 ± 3.46966-3.3915 ± 4.65725
Total Bilirubin, Day 21-0.0855 ± 2.10399-2.5992 ± 5.517760.5130 ± 3.87835-3.4485 ± 2.88056-3.9330 ± 2.82228-3.1065 ± 3.89102
Total Bilirubin, Day 280.1197 ± 1.42169-2.3655 ± 7.17501-1.5105 ± 4.15838-1.9665 ± 3.32770-2.7930 ± 2.63510-0.1995 ± 5.55096
PrimaryPart 1: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

Time frame:
From Baseline (Day 1) and up to Day 28
Reported as:
Mean · μmol/L
Part 1: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST
μmol/LPart 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
ALP, Baseline (Day 1)56.4 ± 20.8257.2 ± 18.9653.7 ± 6.5063.0 ± 5.1472.0 ± 29.3955.0 ± 8.07
ALP, Day 2-4.1 ± 6.35-0.8 ± 3.13-2.5 ± 3.27-3.7 ± 3.50-4.2 ± 7.41-6.2 ± 2.71
ALP, Day 3-3.3 ± 6.00-2.3 ± 3.39-3.0 ± 5.06-4.8 ± 4.02-5.7 ± 9.37-3.3 ± 3.39
ALP, Day 4-1.9 ± 7.74-1.7 ± 3.39-1.2 ± 5.192.0 ± 6.39-2.5 ± 7.48-2.3 ± 2.73
ALP, Day 5-2.5 ± 7.35-3.2 ± 4.07-1.5 ± 4.09-0.8 ± 5.98-4.0 ± 9.27-2.0 ± 3.46
ALP, Day 6-2.2 ± 7.07-3.8 ± 3.54-1.3 ± 5.432.0 ± 6.42-4.5 ± 12.88-2.3 ± 3.39
ALP, Day 7-1.8 ± 8.01-3.0 ± 4.20-3.2 ± 4.322.0 ± 6.63-5.3 ± 9.77-1.0 ± 3.16
ALP, Day 140.4 ± 5.770.8 ± 8.58-0.5 ± 5.750.0 ± 5.150.0 ± 7.35-1.8 ± 3.13
ALP, Day 212.1 ± 12.140.0 ± 4.90-0.8 ± 3.193.8 ± 8.40-1.8 ± 11.48-3.7 ± 3.44
ALP, Day 28-0.3 ± 7.061.8 ± 3.872.0 ± 8.725.5 ± 8.48-3.3 ± 9.40-3.5 ± 3.56
ALT, Baseline (Day 1)13.9 ± 4.3828.5 ± 16.0124.7 ± 9.0316.0 ± 4.3423.8 ± 13.1121.7 ± 3.44
ALT, Day 20.3 ± 1.895.5 ± 11.26-1.5 ± 3.390.0 ± 1.55-4.3 ± 3.780.2 ± 7.19
ALT, Day 31.8 ± 2.445.2 ± 13.04-2.3 ± 3.080.5 ± 2.43-6.3 ± 5.20-1.2 ± 7.14
ALT, Day 42.1 ± 3.871.5 ± 6.02-1.5 ± 4.28-0.2 ± 2.23-5.8 ± 5.64-1.3 ± 6.47
ALT, Day 52.2 ± 3.49-1.3 ± 3.72-2.5 ± 3.730.2 ± 2.48-5.7 ± 6.35-2.5 ± 5.21
ALT, Day 63.5 ± 4.97-3.8 ± 3.87-2.7 ± 5.541.2 ± 3.19-6.0 ± 7.72-2.5 ± 5.39
ALT, Day 74.8 ± 5.96-5.0 ± 5.37-3.6 ± 5.411.3 ± 2.73-5.7 ± 7.45-1.7 ± 6.71
ALT, Day 145.3 ± 5.48-7.0 ± 9.41-3.2 ± 4.450.8 ± 2.17-1.0 ± 6.16-2.0 ± 5.18
ALT, Day 216.6 ± 8.78-2.2 ± 13.500.2 ± 8.402.2 ± 3.60-4.3 ± 6.89-3.0 ± 4.47
ALT, Day 2811.0 ± 17.58-0.3 ± 15.47-0.8 ± 4.120.8 ± 3.19-5.3 ± 8.85-3.5 ± 2.43
AST, Baseline (Day 1)15.0 ± 3.5320.7 ± 9.6520.3 ± 3.2716.2 ± 2.6420.0 ± 8.0721.7 ± 4.27
AST, Day 2-0.8 ± 1.322.3 ± 9.03-1.2 ± 2.04-1.8 ± 1.83-5.0 ± 5.44-3.3 ± 4.84
AST, Day 30.3 ± 2.540.3 ± 6.35-2.2 ± 1.94-2.2 ± 2.64-5.3 ± 6.83-3.8 ± 4.31
AST, Day 40.1 ± 2.33-3.2 ± 3.76-1.0 ± 2.10-2.2 ± 2.32-5.2 ± 6.62-3.8 ± 4.02
AST, Day 50.2 ± 2.44-5.2 ± 5.56-1.8 ± 0.75-2.0 ± 2.28-5.2 ± 6.88-4.7 ± 3.27
AST, Day 60.1 ± 2.18-5.8 ± 6.11-2.0 ± 2.10-1.8 ± 2.64-5.0 ± 7.24-4.5 ± 3.21
AST, Day 71.0 ± 3.16-3.7 ± 7.84-2.0 ± 1.58-1.5 ± 2.17-5.2 ± 7.08-2.5 ± 3.78
AST, Day 142.7 ± 5.79-3.6 ± 5.030.3 ± 2.880.8 ± 0.84-3.0 ± 6.28-2.2 ± 4.96
AST, Day 213.6 ± 7.57-2.6 ± 6.110.5 ± 4.511.3 ± 2.34-4.2 ± 5.78-2.7 ± 2.73
AST, Day 285.3 ± 8.6311.3 ± 17.812.5 ± 4.28-0.5 ± 2.43-4.2 ± 7.44-1.8 ± 3.19
PrimaryPart 2: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. Standard Deviation (SD)=0.0000 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.0000.

Time frame:
From Baseline (Day 1) and up to Day 42
Reported as:
Mean · μmol/L
Part 2: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
μmol/LPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
Direct Bilirubin, Baseline (Day 1)1.6856 ± 0.348051.7670 ± 0.883041.6031 ± 0.747822.5365 ± 1.12089
Direct Bilirubin, Day 20.1368 ± 0.677560.1995 ± 0.43820—0.3420 ± 0.32445
Direct Bilirubin, Day 30.1710 ± 0.0000—0.5130 ± 0.35400—
Direct Bilirubin, Day 50.2565 ± 1.049480.5700 ± 0.42807—-0.0855 ± 0.44262
Direct Bilirubin, Day 60.1710 ± 0.0000—0.8764 ± 0.54412—
Direct Bilirubin, Day 70.4703 ± 0.769500.3135 ± 0.36542—0.7125 ± 0.36542
Direct Bilirubin, Day 8-0.0855 ± 0.12092—0.6413 ± 0.60458—
Direct Bilirubin, Day 110.5130 ± 0.915560.3990 ± 0.31838—0.5700 ± 0.46726
Direct Bilirubin, Day 12-0.3420 ± 0.0000—0.6840 ± 0.48366—
Direct Bilirubin, Day 140.4703 ± 0.660440.3990 ± 0.36940—0.5130 ± 0.30589
Direct Bilirubin, Day 150.2565 ± 0.12092—0.6413 ± 0.42628—
Direct Bilirubin, Day 210.2993 ± 0.782060.2280 ± 0.46726—0.3420 ± 0.35869
Direct Bilirubin, Day 220.0855 ± 0.12092—0.4703 ± 0.53881—
Direct Bilirubin, Day 28-0.2052 ± 0.77800-0.3705 ± 0.52335-0.3206 ± 0.57401-0.6840 ± 0.71739
Direct Bilirubin, Day 35-0.2565 ± 0.44262-0.3135 ± 0.61576-0.2779 ± 0.562980.3135 ± 0.75253
Direct Bilirubin, Day 42-0.1710 ± 0.37464-0.6555 ± 0.464120.1069 ± 0.639420.0285 ± 0.89456
Total Bilirubin, Baseline (Day 1)10.5776 ± 2.9854510.0890 ± 5.907809.5760 ± 4.3692312.8250 ± 6.63163
Total Bilirubin, Day 22.0520 ± 4.886233.5910 ± 1.49466—4.0470 ± 1.90622
Total Bilirubin, Day 30.4275 ± 0.12092—2.9284 ± 1.86301—
Total Bilirubin, Day 51.3253 ± 6.247743.6480 ± 1.09582—2.9070 ± 2.52478
Total Bilirubin, Day 6-1.6245 ± 0.36275—3.1421 ± 2.90044—
Total Bilirubin, Day 72.1375 ± 5.960523.1350 ± 2.20495—3.6195 ± 1.75529
Total Bilirubin, Day 8-1.7955 ± 0.12092—3.5696 ± 3.25149—
Total Bilirubin, Day 112.0520 ± 5.835753.7620 ± 2.69508—3.6195 ± 1.29517
Total Bilirubin, Day 12-1.0260 ± 1.20915—4.2964 ± 2.74733—
Total Bilirubin, Day 141.0688 ± 4.142713.3345 ± 1.83138—2.8215 ± 1.26932
Total Bilirubin, Day 150.0855 ± 1.08824—4.4033 ± 2.53263—
Total Bilirubin, Day 211.8383 ± 3.834811.8810 ± 3.11577—4.1325 ± 2.32816
Total Bilirubin, Day 22-0.5130 ± 0.72549—2.6719 ± 3.49125—
Total Bilirubin, Day 28-2.5308 ± 5.31257-1.9665 ± 3.28525-2.8856 ± 2.53212-4.5030 ± 4.18257
Total Bilirubin, Day 35-1.8525 ± 3.35337-1.8525 ± 4.50534-2.0306 ± 2.422512.1945 ± 4.64845
Total Bilirubin, Day 42-1.2540 ± 2.32376-2.6505 ± 4.28354-0.9619 ± 3.562310.2280 ± 5.78644
PrimaryPart 2: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value. SD=0.00 is defined as following: if all participants analyzed for a specific parameter at a specific time point have the same value, then SD is equal with 0.00.

Time frame:
From Baseline (Day 1) and up to Day 42
Reported as:
Mean · IU/L
Part 2: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST
IU/LPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
ALP, Baseline (Day 1)56.0 ± 16.7859.5 ± 19.6969.0 ± 22.4353.8 ± 10.55
ALP, Day 2-5.8 ± 12.48-1.2 ± 3.92—-0.7 ± 3.50
ALP, Day 30.0 ± 1.41—-0.4 ± 2.20—
ALP, Day 5-6.8 ± 14.312.7 ± 5.09—0.5 ± 2.59
ALP, Day 60.0 ± 1.41—0.3 ± 3.41—
ALP, Day 7-9.0 ± 14.31-0.2 ± 3.66—0.3 ± 3.33
ALP, Day 80.0 ± 1.41—2.9 ± 7.32—
ALP, Day 11-9.0 ± 16.02-5.5 ± 3.89—-2.7 ± 4.08
ALP, Day 120.0 ± 1.41—-5.0 ± 3.34—
ALP, Day 14-7.5 ± 15.151.5 ± 3.56—-4.2 ± 3.60
ALP, Day 153.5 ± 3.54—-2.5 ± 3.70—
ALP, Day 21-9.8 ± 15.59-7.7 ± 6.44—-3.0 ± 4.82
ALP, Day 220.0 ± 1.41—-5.3 ± 5.63—
ALP, Day 28-6.2 ± 11.230.5 ± 9.52-6.4 ± 4.96-2.5 ± 3.15
ALP, Day 35-7.5 ± 7.793.5 ± 17.16-3.5 ± 6.21-4.8 ± 1.83
ALP, Day 42-3.0 ± 7.480.8 ± 8.08-2.5 ± 3.63-0.3 ± 3.72
ALT, Baseline (Day 1)23.6 ± 8.3015.8 ± 4.6219.5 ± 5.7119.8 ± 6.24
ALT, Day 2-2.6 ± 2.410.2 ± 1.72—-0.8 ± 2.32
ALT, Day 3-3.0 ± 1.41—-2.9 ± 3.56—
ALT, Day 5-4.5 ± 4.200.2 ± 2.64—-2.5 ± 2.74
ALT, Day 6-7.0 ± 1.41—-3.9 ± 5.82—
ALT, Day 7-5.5 ± 5.74-1.3 ± 2.07—-1.0 ± 2.97
ALT, Day 8-6.0 ± 2.83—-1.4 ± 8.58—
ALT, Day 11-6.3 ± 6.02-3.3 ± 3.67—-0.3 ± 5.47
ALT, Day 12-8.5 ± 2.12—-4.8 ± 7.19—
ALT, Day 14-4.8 ± 5.85-3.7 ± 4.46—-1.2 ± 3.66
ALT, Day 15-0.5 ± 6.36—-1.4 ± 8.85—
ALT, Day 21-5.5 ± 4.65-3.5 ± 4.04—-1.5 ± 5.47
ALT, Day 22-7.0 ± 0.00—-2.5 ± 9.43—
ALT, Day 28-3.4 ± 7.090.8 ± 3.661.4 ± 5.782.5 ± 8.46
ALT, Day 35-1.2 ± 8.4712.2 ± 25.97-1.1 ± 4.26-1.5 ± 4.51
ALT, Day 421.0 ± 8.39-1.0 ± 4.291.0 ± 2.452.0 ± 4.10
AST, Baseline (Day 1)23.3 ± 7.4517.3 ± 3.4418.9 ± 2.7017.7 ± 3.27
AST, Day 2-4.4 ± 5.81-0.8 ± 1.47—-2.3 ± 2.25
AST, Day 3-2.5 ± 0.71—-1.9 ± 2.23—
AST, Day 5-2.5 ± 1.00-0.5 ± 1.87—-3.7 ± 2.73
AST, Day 6-5.5 ± 0.71—-2.9 ± 3.14—
AST, Day 7-3.3 ± 1.89-1.0 ± 2.10—-3.0 ± 2.45
AST, Day 8-4.5 ± 2.12—-0.9 ± 4.29—
AST, Day 11-5.0 ± 3.16-1.5 ± 1.64—-4.3 ± 3.01
AST, Day 12-5.0 ± 2.83—-3.0 ± 2.45—
AST, Day 14-3.3 ± 2.22-0.7 ± 2.73—-3.8 ± 2.32
AST, Day 15-1.5 ± 2.12—-1.3 ± 3.81—
AST, Day 21-4.0 ± 1.83-1.7 ± 2.25—-2.7 ± 3.83
AST, Day 22-3.5 ± 3.54—-2.3 ± 3.20—
AST, Day 28-1.6 ± 3.130.2 ± 2.563.8 ± 9.083.0 ± 5.73
AST, Day 35-0.8 ± 4.549.0 ± 19.071.6 ± 3.812.5 ± 5.96
AST, Day 420.8 ± 5.34-1.0 ± 2.610.9 ± 3.443.0 ± 5.33
PrimaryPart 3: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of bilirubin. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

Time frame:
From Baseline (Day 1) and up to Day 28
Reported as:
Mean · IU/L
Part 3: Change From Baseline in Liver Panel Parameters: Direct Bilirubin, Total Bilirubin
IU/LPart 3 (Single Dose): VH4011499 200 mg Tablet
Direct Bilirubin, Baseline (Day 1)1.4250 ± 0.69810
Direct Bilirubin, Day 20.7125 ± 0.89456
Direct Bilirubin, Day 30.8265 ± 0.93920
Direct Bilirubin, Day 40.5415 ± 0.92667
Direct Bilirubin, Day 50.4104 ± 0.53531
Direct Bilirubin, Day 60.8835 ± 0.98182
Direct Bilirubin, Day 70.5700 ± 0.79228
Direct Bilirubin, Day 140.5415 ± 0.66154
Direct Bilirubin, Day 210.4275 ± 0.41536
Direct Bilirubin, Day 281.2540 ± 2.25219
Total Bilirubin, Baseline (Day 1)7.6950 ± 3.19912
Total Bilirubin, Day 26.5550 ± 6.58354
Total Bilirubin, Day 36.1275 ± 6.16873
Total Bilirubin, Day 44.5600 ± 5.75401
Total Bilirubin, Day 53.6936 ± 3.29058
Total Bilirubin, Day 66.8970 ± 7.58181
Total Bilirubin, Day 73.5340 ± 5.11821
Total Bilirubin, Day 144.0755 ± 4.44786
Total Bilirubin, Day 210.5415 ± 2.47901
Total Bilirubin, Day 286.7545 ± 13.42355
PrimaryPart 3: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of ALT, ALP and AST. Change from baseline was calculated by subtracting the baseline value from the post-dose visit value.

Time frame:
From Baseline (Day 1) and up to Day 28
Reported as:
Mean · IU/L
Part 3: Change From Baseline in Liver Panel Parameters: ALT, ALP and AST
IU/LPart 3 (Single Dose): VH4011499 200 mg Tablet
ALP, Baseline (Day 1)52.0 ± 8.12
ALP, Day 2-1.3 ± 6.02
ALP, Day 3-1.0 ± 6.29
ALP, Day 42.3 ± 6.31
ALP, Day 55.4 ± 5.73
ALP, Day 62.2 ± 6.52
ALP, Day 72.7 ± 6.47
ALP, Day 142.7 ± 7.17
ALP, Day 210.7 ± 6.02
ALP, Day 284.3 ± 5.50
ALT, Baseline (Day 1)12.7 ± 4.03
ALT, Day 22.5 ± 5.17
ALT, Day 32.3 ± 5.57
ALT, Day 42.3 ± 6.98
ALT, Day 50.8 ± 1.64
ALT, Day 62.5 ± 4.42
ALT, Day 72.3 ± 3.39
ALT, Day 144.8 ± 5.60
ALT, Day 216.5 ± 6.66
ALT, Day 282.3 ± 1.03
AST, Baseline (Day 1)16.7 ± 1.63
AST, Day 20.7 ± 3.50
AST, Day 3-0.3 ± 2.34
AST, Day 4-0.2 ± 2.64
AST, Day 5-0.4 ± 1.52
AST, Day 60.5 ± 1.87
AST, Day 7-0.3 ± 1.86
AST, Day 142.7 ± 3.27
AST, Day 214.3 ± 7.79
AST, Day 281.8 ± 2.56
PrimaryPart 1: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters
ParticipantsPart 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
ALT, Increase to Grade 1020000
ALT, Increase to Grade 2000000
ALT, Increase to Grade 3000000
ALT, Increase to Grade 4000000
ALP, Increase to Grade 1000000
ALP, Increase to Grade 2000000
ALP, Increase to Grade 3000000
ALP, Increase to Grade 4000000
AST, Increase to Grade 1020000
AST, Increase to Grade 2000000
AST, Increase to Grade 3000000
AST, Increase to Grade 4000000
Total Bilirubin, Increase to Grade 1000000
Total Bilirubin, Increase to Grade 2000000
Total Bilirubin, Increase to Grade 3000000
Total Bilirubin, Increase to Grade 4000000
Direct Bilirubin, Increase to Grade 1000000
Direct Bilirubin, Increase to Grade 2000000
Direct Bilirubin, Increase to Grade 3000000
Direct Bilirubin, Increase to Grade 4000000
PrimaryPart 2: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.

Time frame:
Up to Day 42
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters
ParticipantsPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
ALT, Increase to Grade 10100
ALT, Increase to Grade 20000
ALT, Increase to Grade 30000
ALT, Increase to Grade 40000
ALP, Increase to Grade 10000
ALP, Increase to Grade 20000
ALP, Increase to Grade 30000
ALP, Increase to Grade 40000
AST, Increase to Grade 10100
AST, Increase to Grade 20000
AST, Increase to Grade 30000
AST, Increase to Grade 40000
Total Bilirubin, Increase to Grade 10001
Total Bilirubin, Increase to Grade 20000
Total Bilirubin, Increase to Grade 30000
Total Bilirubin, Increase to Grade 40000
Direct Bilirubin, Increase to Grade 10000
Direct Bilirubin, Increase to Grade 20000
Direct Bilirubin, Increase to Grade 30000
Direct Bilirubin, Increase to Grade 40000
PrimaryPart 3: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters

Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of the liver panel parameters: ALT, ALP, AST, total bilirubin and direct bilirubin. The number of participants with any grade increase (from grade 1 \[mild\] to grade 4 \[potentially life-threatening\]) have been presented.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Maximum Toxicity Grade Increase From Baseline for Liver Panel Parameters
ParticipantsPart 3 (Single Dose): VH4011499 200 mg Tablet
ALT, Increase to Grade 10
ALT, Increase to Grade 20
ALT, Increase to Grade 30
ALT, Increase to Grade 40
ALP, Increase to Grade 10
ALP, Increase to Grade 20
ALP, Increase to Grade 30
ALP, Increase to Grade 40
AST, Increase to Grade 10
AST, Increase to Grade 20
AST, Increase to Grade 30
AST, Increase to Grade 40
Total Bilirubin, Increase to Grade 11
Total Bilirubin, Increase to Grade 20
Total Bilirubin, Increase to Grade 30
Total Bilirubin, Increase to Grade 40
Direct Bilirubin, Increase to Grade 10
Direct Bilirubin, Increase to Grade 20
Direct Bilirubin, Increase to Grade 30
Direct Bilirubin, Increase to Grade 40
PrimaryPart 1: Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinity (0-inf) Following Single Dose Administration of VH4011499

Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis to determine AUC(0-inf). For AUC, a linear trapezoidal method was employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method was used for those arising from decreasing concentrations. Geometric Coefficient of Variation was expressed in percentages.

Time frame:
At Day 1
Reported as:
Geometric mean · Hour nanogram per milliliter (h*ng/mL)
Part 1: Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinity (0-inf) Following Single Dose Administration of VH4011499
Hour nanogram per milliliter (h*ng/mL)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
Part 1: Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinity (0-inf) Following Single Dose Administration of VH40114992759.51 ± 53.698458.88 ± 20.3911627.63 ± 36.0124391.58 ± 34.1636327.28 ± 48.29
PrimaryPart 2: AUC Over a Dosing Interval From Time of Dosing to the Time of the Subsequent Dose (0-t) Following Repeat Dose Administration of VH4011499

Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine AUC(0-t). For AUC, a linear trapezoidal method was employed for all incremental trapezoids arising from increasing concentrations and the logarithmic trapezoidal method was used for those arising from decreasing concentrations.

Time frame:
At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
Reported as:
Geometric mean · h*ng/mL
Part 2: AUC Over a Dosing Interval From Time of Dosing to the Time of the Subsequent Dose (0-t) Following Repeat Dose Administration of VH4011499
h*ng/mLPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
Day 1/24211.67 ± 15.365385.19 ± 21.744879.14 ± 36.00
Day 14/1595735.06 ± 56.77168459.8 ± 54.17139259.6 ± 24.66
PrimaryPart 1: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of VH4011499.

Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Cmax.

Time frame:
At Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Part 1: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of VH4011499.
nanogram per milliliter (ng/mL)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
Part 1: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of VH4011499.26.85 ± 26.18106.90 ± 17.24168.88 ± 36.25328.95 ± 37.97557.81 ± 52.86
PrimaryPart 1: Time to Maximum Observed Plasma Concentration (Tmax) Following Single Dose Administration of VH4011499

Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Tmax.

Time frame:
At Day 1
Reported as:
Geometric mean · hours
Part 1: Time to Maximum Observed Plasma Concentration (Tmax) Following Single Dose Administration of VH4011499
hoursPart 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
Part 1: Time to Maximum Observed Plasma Concentration (Tmax) Following Single Dose Administration of VH401149911.30 ± 9.5110.26 ± 14.779.28 ± 11.567.86 ± 22.838.79 ± 24.60
PrimaryPart 1: Apparent Terminal Half-life (T1/2) Following Single Dose Administration of VH4011499

Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine T1/2.

Time frame:
At Day 1
Reported as:
Geometric mean · hours
Part 1: Apparent Terminal Half-life (T1/2) Following Single Dose Administration of VH4011499
hoursPart 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiB
Part 1: Apparent Terminal Half-life (T1/2) Following Single Dose Administration of VH401149963.97 ± 21.0754.44 ± 23.8661.61 ± 29.5766.32 ± 24.7555.90 ± 25.33
PrimaryPart 2: Cmax Following Repeat Dose Administration of VH4011499

Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Cmax.

Time frame:
At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
Reported as:
Geometric mean · ng/mL
Part 2: Cmax Following Repeat Dose Administration of VH4011499
ng/mLPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
Day 1260.89 ± 19.62—321.37 ± 53.14
Day 2—348.24 ± 20.46—
Day 141272.25 ± 42.47—1509.90 ± 22.56
Day 15—1913.76 ± 22.93—
PrimaryPart 2: Tmax Following Repeat Dose Administration of VH4011499

Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine Tmax.

Time frame:
At Days 1 and 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Days 2 and 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
Reported as:
Geometric mean · hours
Part 2: Tmax Following Repeat Dose Administration of VH4011499
hoursPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
Day 110.71 ± 41.53—9.50 ± 51.00
Day 2—8.11 ± 22.96—
Day 144.80 ± 30.46—5.99 ± 42.79
Day 15—5.27 ± 32.11—
PrimaryPart 2: T1/2 Following Repeat Dose Administration of VH4011499

Blood samples were collected as assessed by protocol, at specific time points for PK analysis to determine T1/2.

Time frame:
At Day 14 for Part 2 (MAD): VH4011499 200 mg PiB and Part 2 (MAD): VH4011499 400 mg PiB groups, and at Day 15 for Part 2 (MAD): VH4011499 300 mg + Midazolam PiB group
Reported as:
Geometric mean · hours
Part 2: T1/2 Following Repeat Dose Administration of VH4011499
hoursPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiB
Day 1451.17 ± 16.68—60.36 ± 21.81
Day 15—66.47 ± 19.10—

Adverse events

Collected over All-cause mortality, non-serious adverse events and serious adverse events were collected up to 28-days following final dose of VH4011499 or placebo (Day 28 for Part 1 and Part 3, and Day 42 for Part 2).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)0/10 (0%)1/10 (10%)3/10 (30%)
Part 1 (SAD): VH4011499 25 mg PiB0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1 (SAD): VH4011499 125 mg PiB0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1 (SAD): VH4011499 200 mg PiB0/6 (0%)0/6 (0%)3/6 (50%)
Part 1 (SAD): VH4011499 625 mg PiB0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1 (SAD): VH4011499 1875 mg PiB0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 2 Multiple Ascending Dose (MAD): Placebo PiB0/7 (0%)0/7 (0%)2/7 (28.6%)
Part 2 (MAD): VH4011499 200 mg PiB0/6 (0%)0/6 (0%)3/6 (50%)
Part 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiB0/8 (0%)0/8 (0%)3/8 (37.5%)
Part 2 (MAD): VH4011499 400 mg PiB0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 3 (Single Dose): VH4011499 200 mg Tablet0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent serious events
Most frequent serious events
EventPart 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiBPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiBPart 3 (Single Dose): VH4011499 200 mg Tablet
Non-cardiac chest painGeneral disorders1/100/60/60/60/60/60/70/60/80/60/6
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPart 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiBPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiBPart 3 (Single Dose): VH4011499 200 mg Tablet
DiarrhoeaGastrointestinal disorders0/100/60/60/60/60/60/72/60/80/60/6
NauseaGastrointestinal disorders0/100/60/60/60/60/60/72/60/80/60/6
VomitingGastrointestinal disorders0/100/60/60/60/60/60/72/60/80/60/6
Activated partial thromboplastin time prolongedInvestigations0/100/60/62/60/60/60/70/60/80/60/6
HeadacheNervous system disorders0/100/60/60/60/60/60/72/61/80/60/6
SomnolenceNervous system disorders0/100/60/60/60/60/60/70/62/80/60/6
Blood creatine phosphokinase increasedInvestigations2/101/60/60/60/60/60/70/60/80/60/6
Infrequent bowel movementsGastrointestinal disorders0/100/60/60/60/60/60/71/60/80/60/6
Influenza like illnessGeneral disorders0/100/60/60/60/60/60/71/60/80/60/6
Medical device site dermatitisGeneral disorders0/100/61/60/60/60/60/70/60/80/61/6

Baseline characteristics

Baseline characteristics presented based on Exposed population.

Age, Continuous
Age, Continuous(Years)Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiBPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiBPart 3 (Single Dose): VH4011499 200 mg TabletTotal
Mean37.8 ± 11.1735.3 ± 6.1236.5 ± 7.4845.8 ± 8.0840.0 ± 12.0539.8 ± 7.7837.6 ± 11.1835.5 ± 13.1038.9 ± 11.8132.3 ± 3.8337.2 ± 9.9137.9 ± 9.72
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiBPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiBPart 3 (Single Dose): VH4011499 200 mg TabletTotal
Male9665567576668
Female100110011005
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1 Single Ascending Dose (SAD): Placebo Powder-in-a-bottle (PiB)Part 1 (SAD): VH4011499 25 mg PiBPart 1 (SAD): VH4011499 125 mg PiBPart 1 (SAD): VH4011499 200 mg PiBPart 1 (SAD): VH4011499 625 mg PiBPart 1 (SAD): VH4011499 1875 mg PiBPart 2 Multiple Ascending Dose (MAD): Placebo PiBPart 2 (MAD): VH4011499 200 mg PiBPart 2 (MAD): VH4011499 300 mg + Midazolam (MDZ) PiBPart 2 (MAD): VH4011499 400 mg PiBPart 3 (Single Dose): VH4011499 200 mg TabletTotal
Asian200202100007
Black or African American3331213354129
Native Hawaiian or other Pacific Islander000000000011
White5222413332330
Multiple011102000016
08

Study locations

2 sites
  • GSK Investigational Site
    Las Vegas, Nevada 89113, United States
  • GSK Investigational Site
    Austin, Texas 78744, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Apr 2023, 6 months.

Results were first posted in Apr 2025, 1 year 11 months after primary completion.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 6 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
May 26, 2022
StartActual
Oct 3, 2022
Primary completionActual
Apr 24, 2023
CompletionActual
Apr 24, 2023
Results first posted
Apr 1, 2025
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05393271
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
May 26, 2022
Start date
Oct 3, 2022
Primary completion
Apr 24, 2023
Completion
Apr 24, 2023
Results posted
Apr 1, 2025
Last update
Apr 1, 2025

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dezecapavir

Start the discussion